<DOC>
	<DOCNO>NCT02845843</DOCNO>
	<brief_summary>This placebo-controlled clinical trial ass feasibility , efficacy safety combination lopinavir/ritonavir Interferon beta-1b hospitalize patient MERS .</brief_summary>
	<brief_title>MERS-CoV Infection tReated With A Combination Lopinavir /Ritonavir Interferon Beta-1b</brief_title>
	<detailed_description>The aim study investigate feasibility , efficacy safety lopinavir /ritonavir recombinant Interferon beta-1b combination give optimal supportive care compare placebo optimal supportive care patient laboratory-confirmed MERS-CoV infection require hospital admission .</detailed_description>
	<mesh_term>Coronavirus Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Inclusion criterion : 1 . All patient laboratory confirm ( RTPCR ) MERSCoV require hospital admission illness severity . 2 . More equal 18 year age . Exclusion criterion : 1 . History acute severe neuropsychiatric disorder schizophrenia etc . 2 . History hypersensitivity reaction lopinavir /ritonavir , component formulation recombinant interferon beta1b ( e.g. , toxic epidermal necrolysis , StevensJohnson syndrome , erythema multiforme , urticaria , angioedema ) 3 . Fulminant liver failure 4 . Patients medication contraindicate study drug replace stop study period ( e.g Cytochrome P450 3A4 ( CYP3A ) inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Middle East Respiratory Syndrome Coronavirus</keyword>
	<keyword>MERS-CoV</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Lopinavir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Interferon beta</keyword>
</DOC>